All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-01-09T09:46:15.000Z

What does the future hold for patients with relapsed AML?

Bookmark this article

During the 4th National Cancer Research Institute (NCRI) AML Academy Meeting, the AML Hub was pleased to speak to Pramila Krishnamurthy, King’s College Hospital NHS Foundation Trust, London, UK. We asked, What does the future hold for patients with relapsed acute myeloid leukemia (AML)?

What does the future hold for patients with relapsed AML?

Krishnamurthy discusses the changing landscape of frontline therapy and challenges facing clinicians. Focusing on topics such as the use of novel doublet and triplet combination agents, menin inhibitors, and the potential of immune and CAR T-cell therapies, Krishnamurthy presents her thoughts on what the future holds for patients with relapsed AML, including the importance of clinical trials specifically for this subgroup.

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 6 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox